ClinicalTrials.gg
CompletedNCT03376516Updated Jan 19, 2021Results posted

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

A Phase 3 interventional study of Wilate in Severe Hemophilia A, sponsored by Octapharma. Completed at 3 sites in 2 countries. Open to male participants aged 1 Year to 11 Years. Per ClinicalTrials.gov, last updated 2021-01-19.

Sponsored by Octapharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
1 Year to 11 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 15 studies in Hemophilia A by Octapharma — 3 open to participants now, 3 under way, none of them phase 3. Hemophilia A · Octapharma.

Enrollment
11th of 12
11 · median 34
Started
2017
the only one that year
Phase 3
8 of 15
none open now
Registered
11th of 15
by date

Among the 15 studies in Hemophilia A by Octapharma, this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2017, is one of 8 in phase 3, and was the 11th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

3 of the 15 studies in Hemophilia A by Octapharma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 1 Year to 11 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hemophilia A by Octapharma, or all of them as a file.
02

Study summary

A prospective, non-controlled, international, multi-centre phase 3 study to investigate the pharmacokinetics, efficacy, safety, and immunogenicity of Wilate in previously treated children with severe haemophilia A

03

Conditions studied

  • Severe Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
1 Year to 11 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Severe haemophilia A (\<1% FVIII:C) according to medical history
  2. Male patients aged 1 to \<12 years
  3. Previous treatment with a FVIII concentrate for at least 50 exposure days (EDs)
  4. Immunocompetence ( >200/μL)
  5. Voluntarily given, fully informed written and signed consent obtained by the patient's parent(s) or legal guardian and, depending on the children's developmental stage and intellectual capacity, informed assent by the patients before any study-related procedures are performed

The interval between the Screening Visit and the PK Visit should not exceed 30 days. If the 30-day interval is exceeded, determination of the CD4+ count is to be repeated and must be >200/μL for patients to be enrolled (i.e., inclusion criterion no. 4).

Exclusion criteria

Exclusion Criteria:

  1. Any coagulation disorders other than haemophilia A
  2. History of FVIII inhibitor activity (≥0.6 BU) or detectable FVIII inhibitory antibodies (≥0.6 BU using the Nijmegen modification of the Bethesda assay) at screening, as determined by the central laboratory
  3. Severe liver or kidney diseases ( [ALAT] and aspartate transaminase [ASAT] levels >5 times of , creatinine >120 μmol/L)
  4. Patients receiving or scheduled to receive immunomodulating drugs (other than antiretroviral chemotherapy), such as alpha-interferon, prednisone (equivalent to >10 mg/day), or similar drugs
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    All patients

    All patients will receive Wilate for prophylactic treatment. Patients will also receive Wilate for treatment of breakthrough bleeding events as required

    Drug: Wilate

Interventions

  • DrugWilate

    von Willebrand factor / Factor VIII (plasma derived)

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Assessment (Area Under the Curve (AUC)) of FVIII:C

    PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate AUC is hours (h) x international units (IU)/decilitre (dL).

    Time frame: 0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate

  2. Pharmacokinetic (PK) Assessment (Area Under the Curve [AUC] Normalised (AUCNorm)) of FVIII:C for Wilate

    PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The mean area under the curve normalised for the administered dose (AUCnorm) was calculated for Wilate. The units of measure used were AUC divided by dose.

    Time frame: 0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate

  3. Pharmacokinetic (PK) Assessment (Half-life (h)) of FVIII:C

    PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate half-life is hours.

    Time frame: 0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate

  4. Pharmacokinetic (PK) Assessment (Maximum Plasma Concentration) for FVIII:C

    PK assessments of FVIII:C were determined using the one-stage (OS) assays. The maximum plasma concentration of FVIII:C was calculated based on the FVIII:C values measured in the patients participating in the PK study. Units of measure for maximum plasma concentration are international units (IU)/ decilitre (dL)

    Time frame: 0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate

  5. Pharmacokinetic (PK) Assessment (Time to Reach Maximum Plasma Concentration (Tmax)) of FVIII:C

    PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate Tmax is hours (h).

    Time frame: 48 h following a single dose of Wilate

  6. Pharmacokinetic (PK) Assessment (Mean Residence Time (MRT)) of FVIII:C

    PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate MRT is hours.

    Time frame: 48 h following a single dose of Wilate

  7. Pharmacokinetic (PK) Assessment (Volume of Distribution (Vd)) of FVIII:C

    PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate Vd is decilitre (dL)/ kilograms (kg).

    Time frame: 0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate

  8. Pharmacokinetic (PK) Assessment (Clearance) of FVIII:C

    PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate clearance are decilitre (dL)/ hours (h)/ kilograms (kg).

    Time frame: 0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate

  9. Incremental In Vivo Recovery (IVR) of FVIII:C

    The incremental IVR was determined from all patients at baseline was determined using the one-stage (OS) assay (standardised to 50 IU/kg). The units of measure to calculate IVR is kilograms (kg) / deciliter (dL)

    Time frame: 48 h following a single dose of Wilate

Secondary outcomes

  1. Total Annualized Bleeding Rate (TABR)

    The total number of bleeding events (BEs) in the time period between the first dose of IMP and the study completion visit, divided by the duration (in years) between the first dose of IMP and the study completion visit. Surgery periods, and BEs occurring within these periods, will be excluded from the calculation of TABR.

    Time frame: 6 months

  2. Spontaneous Annualized Bleeding Rate (SABR)

    The SABR was calculated in analogy to the TABR. The total number of spontaneous bleeding events (BEs) in the time period between the first dose of IMP and the study completion visit, divided by the duration (in years) between the first dose of IMP and the study completion visit. Surgery periods, and BEs occurring within these periods, will be excluded from the calculation of the SABR.

    Time frame: 6 months

  3. Efficacy of Wilate in the Treatment of Breakthrough Bleeding Events (BEs)

    The proportion of BEs successfully treated with Wilate was assessed by the patient (together with the investigator in case of on-site treatment) in a patient diary. The treatment efficacy for all BEs was assessed using a pre-defined four-point scale: 'excellent', 'good', 'moderate', 'none'. 'Excellent' was defined as "Abrupt pain relief and/or unequivocal improvement in objective signs of bleeding within approximately 8 hours after a single injection" (best outcome); 'good 'was defined as "definite pain relief and/or improvement in signs of bleeding within approximately 8-12 hours after an injection, requiring up to 2 injections for complete resolution". All efficacy ratings assessed as either 'excellent' or 'good' were considered 'successfully treated'. 'Moderate' was defined as "probable or slight beneficial effect within approximately 12 hours after the first injection" and 'none' defined as "no improvement within 12 hours, or worsening of symptoms".

    Time frame: 6 months

  4. Wilate Consumption Data: Average Dose of Wilate Per Week of Study

    The average consumption of Wilate per week of the study (IU/kg) for all patients receiving prophylaxis

    Time frame: 6 months

  5. Incremental in Vivo Recovery (IVR) of Wilate Over Time

    The rise in FVIII:C activity in IU/dl per unit dose administered in IU/kg was determined for all patients at baseline, 3 and 6 months, using the one-stage (OS) assay.

    Time frame: Baseline, and 3 and 6 months of treatment

  6. Association Between ABO Blood Type and the FVIII:C Half-life of Wilate (OS Assay)

    Analysis of variance (ANOVA) was used in an exploratory sense to assess a possible association between the ABO blood type and the FVIII:C half-life of Wilate. This was analysed by calculating the mean square in a one-stage (OS) assay.

    Time frame: 6 months

  7. Association Between VWF:Ag Concentration and the FVIII:C Half-life of Wilate

    Analysis of variance (ANOVA) was used in an exploratory sense to assess a possible association between VWF:Ag with the FVIII:C half-life of Wilate. This was analysed by calculating the mean square in a one-stage (OS) assay.

    Time frame: 6 months

  8. Safety and Tolerability of Wilate by Monitoring The Number of Adverse Events (AEs) Throughout the Study

    At each visit (whether scheduled or unscheduled) , AEs will be documented by the investigator throughout the study. In addition, the investigator will check the patient diaries for any documented event.

    Time frame: 6 months

  9. Immunogenicity of Wilate: Number of Participants With FVIII Inhibitor Activity at 6 Months

    FVIII inhibitor activity was determined at each study visit: screening, PK, Day 14 visit, Day 30 visit, 3 Months visit and 6 Months visit before injection.

    Time frame: 6 months

  10. Virus Safety Measured by the Number With Parvovirus B19 Seroconversions Between Baseline (BL) and End of Study

    Virus safety was evaluated by taking a plasma sample for parvovirus B19 antibody testing before the first injection of Wilate at the PK visit. All patients negative at screening were tested again at the Study Completion visit. The number of Parvovirus B19 seroconversions between BL and end of study was recorded

    Time frame: 6 months

07

Results

Posted Dec 24, 2019

Participant flow

Participant flow — Overall Study
MilestoneWilate
Started11
Received treatment10
Saf population10
Fas population10
Pk population10
Pp population9
Surg population2
Completed9
Not completed2
Withdrew: Not treated1
Withdrew: Consent withdrawn1

Outcome measures

PrimaryPharmacokinetic (PK) Assessment (Area Under the Curve (AUC)) of FVIII:C

PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate AUC is hours (h) x international units (IU)/decilitre (dL).

Time frame:
0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate
Reported as:
Mean · h*IU/dL
Pharmacokinetic (PK) Assessment (Area Under the Curve (AUC)) of FVIII:C
h*IU/dLWilate
1-<6 years768.8 ± 288.5
6-<12 years671.9 ± 289.7
Total720.3 ± 277.3
PrimaryPharmacokinetic (PK) Assessment (Area Under the Curve [AUC] Normalised (AUCNorm)) of FVIII:C for Wilate

PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The mean area under the curve normalised for the administered dose (AUCnorm) was calculated for Wilate. The units of measure used were AUC divided by dose.

Time frame:
0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate
Reported as:
Mean · h*kg/dL
Pharmacokinetic (PK) Assessment (Area Under the Curve [AUC] Normalised (AUCNorm)) of FVIII:C for Wilate
h*kg/dLWilate
1-<6 years15.38 ± 5.77
6-<12 years13.44 ± 5.79
Total14.41 ± 5.55
PrimaryPharmacokinetic (PK) Assessment (Half-life (h)) of FVIII:C

PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate half-life is hours.

Time frame:
0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate
Reported as:
Mean · hours
Pharmacokinetic (PK) Assessment (Half-life (h)) of FVIII:C
hoursWilate
1-<6 years8.28 ± 1.51
6-<12 years9.35 ± 2.40
Total8.82 ± 1.97
PrimaryPharmacokinetic (PK) Assessment (Maximum Plasma Concentration) for FVIII:C

PK assessments of FVIII:C were determined using the one-stage (OS) assays. The maximum plasma concentration of FVIII:C was calculated based on the FVIII:C values measured in the patients participating in the PK study. Units of measure for maximum plasma concentration are international units (IU)/ decilitre (dL)

Time frame:
0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate
Reported as:
Mean · IU/dL
Pharmacokinetic (PK) Assessment (Maximum Plasma Concentration) for FVIII:C
IU/dLWilate
1-<6 years83.0 ± 16.5
6-<12 years78.94 ± 26.56
Total80.99 ± 20.94
PrimaryPharmacokinetic (PK) Assessment (Time to Reach Maximum Plasma Concentration (Tmax)) of FVIII:C

PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate Tmax is hours (h).

Time frame:
48 h following a single dose of Wilate
Reported as:
Mean · hours
Pharmacokinetic (PK) Assessment (Time to Reach Maximum Plasma Concentration (Tmax)) of FVIII:C
hoursWilate
1-<6 years0.25 ± 0.00
6-<12 years0.25 ± 0.00
Total0.25 ± 0.00
PrimaryPharmacokinetic (PK) Assessment (Mean Residence Time (MRT)) of FVIII:C

PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate MRT is hours.

Time frame:
48 h following a single dose of Wilate
Reported as:
Mean · hours
Pharmacokinetic (PK) Assessment (Mean Residence Time (MRT)) of FVIII:C
hoursWilate
1-<6 years11.47 ± 2.34
6-<12 years12.56 ± 3.53
Total12.01 ± 2.88
PrimaryPharmacokinetic (PK) Assessment (Volume of Distribution (Vd)) of FVIII:C

PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate Vd is decilitre (dL)/ kilograms (kg).

Time frame:
0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate
Reported as:
Mean · dL/kg
Pharmacokinetic (PK) Assessment (Volume of Distribution (Vd)) of FVIII:C
dL/kgWilate
1-<6 years0.784 ± 0.177
6-<12 years1.081 ± 0.494
Total0.933 ± 0.384
PrimaryPharmacokinetic (PK) Assessment (Clearance) of FVIII:C

PK assessments of the factor VIII coagulant activity (FVIII:C) for Wilate were determined using the one-stage (OS) assay. The units of measure to calculate clearance are decilitre (dL)/ hours (h)/ kilograms (kg).

Time frame:
0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate
Reported as:
Mean · dL/h/kg
Pharmacokinetic (PK) Assessment (Clearance) of FVIII:C
dL/h/kgWilate
1-<6 years0.071 ± 0.019
6-<12 years0.098 ± 0.074
Total0.084 ± 0.053
PrimaryIncremental In Vivo Recovery (IVR) of FVIII:C

The incremental IVR was determined from all patients at baseline was determined using the one-stage (OS) assay (standardised to 50 IU/kg). The units of measure to calculate IVR is kilograms (kg) / deciliter (dL)

Time frame:
48 h following a single dose of Wilate
Reported as:
Mean · kg/dL
Incremental In Vivo Recovery (IVR) of FVIII:C
kg/dL1-<6 Years6-<12 YearsTotal
Incremental In Vivo Recovery (IVR) of FVIII:C1.65 ± 0.331.57 ± 0.531.61 ± 0.42
SecondaryTotal Annualized Bleeding Rate (TABR)

The total number of bleeding events (BEs) in the time period between the first dose of IMP and the study completion visit, divided by the duration (in years) between the first dose of IMP and the study completion visit. Surgery periods, and BEs occurring within these periods, will be excluded from the calculation of TABR.

Time frame:
6 months
Reported as:
Mean · Bleeding events per year (TABR)
Total Annualized Bleeding Rate (TABR)
Bleeding events per year (TABR)Wilate
1-<6 years6.47 ± 6.61
6-<12 years10.62 ± 9.06
Total8.54 ± 7.79
SecondarySpontaneous Annualized Bleeding Rate (SABR)

The SABR was calculated in analogy to the TABR. The total number of spontaneous bleeding events (BEs) in the time period between the first dose of IMP and the study completion visit, divided by the duration (in years) between the first dose of IMP and the study completion visit. Surgery periods, and BEs occurring within these periods, will be excluded from the calculation of the SABR.

Time frame:
6 months
Reported as:
Mean · Spontaneous bleeding events per year
Spontaneous Annualized Bleeding Rate (SABR)
Spontaneous bleeding events per yearWilate
1-<6 years2.70 ± 2.93
6-<12 years1.20 ± 2.68
Total1.95 ± 2.76
SecondaryEfficacy of Wilate in the Treatment of Breakthrough Bleeding Events (BEs)

The proportion of BEs successfully treated with Wilate was assessed by the patient (together with the investigator in case of on-site treatment) in a patient diary. The treatment efficacy for all BEs was assessed using a pre-defined four-point scale: 'excellent', 'good', 'moderate', 'none'. 'Excellent' was defined as "Abrupt pain relief and/or unequivocal improvement in objective signs of bleeding within approximately 8 hours after a single injection" (best outcome); 'good 'was defined as "definite pain relief and/or improvement in signs of bleeding within approximately 8-12 hours after an injection, requiring up to 2 injections for complete resolution". All efficacy ratings assessed as either 'excellent' or 'good' were considered 'successfully treated'. 'Moderate' was defined as "probable or slight beneficial effect within approximately 12 hours after the first injection" and 'none' defined as "no improvement within 12 hours, or worsening of symptoms".

Time frame:
6 months
Reported as:
Count of units · Bleeding Events (BEs)
Efficacy of Wilate in the Treatment of Breakthrough Bleeding Events (BEs)
Bleeding Events (BEs)1-<6 Years6-<12 YearsTotal
Excellent7916
Good9817
Moderate112
None000
SecondaryWilate Consumption Data: Average Dose of Wilate Per Week of Study

The average consumption of Wilate per week of the study (IU/kg) for all patients receiving prophylaxis

Time frame:
6 months
Reported as:
Mean · IU/kg per week
Wilate Consumption Data: Average Dose of Wilate Per Week of Study
IU/kg per week1-<6 Years6-<12 YearsTotal
Wilate Consumption Data: Average Dose of Wilate Per Week of Study58.52 ± 14.8568.08 ± 19.0263.30 ± 16.86
SecondaryIncremental in Vivo Recovery (IVR) of Wilate Over Time

The rise in FVIII:C activity in IU/dl per unit dose administered in IU/kg was determined for all patients at baseline, 3 and 6 months, using the one-stage (OS) assay.

Time frame:
Baseline, and 3 and 6 months of treatment
Reported as:
Mean · kg/dL
Incremental in Vivo Recovery (IVR) of Wilate Over Time
kg/dL1-<6 Years6-<12 YearsTotal
Baseline1.65 ± 0.331.57 ± 0.531.61 ± 0.42
3 months1.55 ± 0.141.56 ± 0.571.56 ± 0.39
6 months1.63 ± 0.241.32 ± 0.451.48 ± 0.38
SecondaryAssociation Between ABO Blood Type and the FVIII:C Half-life of Wilate (OS Assay)

Analysis of variance (ANOVA) was used in an exploratory sense to assess a possible association between the ABO blood type and the FVIII:C half-life of Wilate. This was analysed by calculating the mean square in a one-stage (OS) assay.

Time frame:
6 months
Reported as:
Number · Correlation coefficient
Association Between ABO Blood Type and the FVIII:C Half-life of Wilate (OS Assay)
Correlation coefficientWilate
1-<6 years0.185
6-<12 years6.100
Total0.922
Statistical analysis
  • Wilate · ANOVA · p = 0.9593 (P-Value for patients aged 1-\<6 years (N=5))
  • Wilate · ANOVA · p = 0.3752 (P-Value for patients aged 6-\<12 years (N=5))
  • Wilate · ANOVA · p = 0.8273 (P-Value for total PK population (N=10))
SecondaryAssociation Between VWF:Ag Concentration and the FVIII:C Half-life of Wilate

Analysis of variance (ANOVA) was used in an exploratory sense to assess a possible association between VWF:Ag with the FVIII:C half-life of Wilate. This was analysed by calculating the mean square in a one-stage (OS) assay.

Time frame:
6 months
Reported as:
Number · Correlation coefficient
Association Between VWF:Ag Concentration and the FVIII:C Half-life of Wilate
Correlation coefficientWilate
1-<6 years0.121
6-<12 years0.006
Total0.003
Statistical analysis
  • Wilate · ANOVA · p = 0.8536
  • Wilate · ANOVA · p = 0.9791 (P-Value for patients aged 6-\<12 years (N=5))
  • Wilate · ANOVA · p = 0.9791 (P-Value for total PK population (N=10))
SecondarySafety and Tolerability of Wilate by Monitoring The Number of Adverse Events (AEs) Throughout the Study

At each visit (whether scheduled or unscheduled) , AEs will be documented by the investigator throughout the study. In addition, the investigator will check the patient diaries for any documented event.

Time frame:
6 months
Reported as:
Number · Adverse events
Safety and Tolerability of Wilate by Monitoring The Number of Adverse Events (AEs) Throughout the Study
Adverse eventsWilate
Safety and Tolerability of Wilate by Monitoring The Number of Adverse Events (AEs) Throughout the Study6
SecondaryImmunogenicity of Wilate: Number of Participants With FVIII Inhibitor Activity at 6 Months

FVIII inhibitor activity was determined at each study visit: screening, PK, Day 14 visit, Day 30 visit, 3 Months visit and 6 Months visit before injection.

Time frame:
6 months
Reported as:
Count of participants · Participants
Immunogenicity of Wilate: Number of Participants With FVIII Inhibitor Activity at 6 Months
ParticipantsWilate
Immunogenicity of Wilate: Number of Participants With FVIII Inhibitor Activity at 6 Months0
Statistical analysis
  • Wilate · Pearson-copper: 0 · 95% CI 0 to 30.85
SecondaryVirus Safety Measured by the Number With Parvovirus B19 Seroconversions Between Baseline (BL) and End of Study

Virus safety was evaluated by taking a plasma sample for parvovirus B19 antibody testing before the first injection of Wilate at the PK visit. All patients negative at screening were tested again at the Study Completion visit. The number of Parvovirus B19 seroconversions between BL and end of study was recorded

Time frame:
6 months
Reported as:
Number · Participants with seroconversions
Virus Safety Measured by the Number With Parvovirus B19 Seroconversions Between Baseline (BL) and End of Study
Participants with seroconversionsWilate
Virus Safety Measured by the Number With Parvovirus B19 Seroconversions Between Baseline (BL) and End of Study1

Adverse events

Collected over Between the screening visit and the follow up contact visit (30 days after the 6-month study completion visit). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Wilate0/10 (0%)1/10 (10%)3/10 (30%)
Most frequent serious events
Most frequent serious events
EventWilate
CryptochidismCongenital, familial and genetic disorders1/10
Most frequent other events
Most frequent other events
EventWilate
Respiratory tract infectionInfections and infestations1/10
VaricellaInfections and infestations1/10
Viral upper respiratory tract infectionInfections and infestations1/10
HeadacheNervous system disorders1/10
Parvovirus B19 test positiveInvestigations1/10

Baseline characteristics

The safety (SAF) population included all patients who received at least one injection of Wilate during the study (n=10).

Age, Customized
Age, Customized(years)Wilate
1-<6 years4.0 ± 1.2
6-<12 years9.8 ± 0.8
Total6.9 ± 3.2
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Wilate
1-<6 years — Female0
1-<6 years — Male5
6-<12 years — Female0
6-<12 years — Male5
Total — Female0
Total — Male10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Wilate
1-<6 years — American Indian or Alaska Native0
1-<6 years — Asian0
1-<6 years — Native Hawaiian or Other Pacific Islander0
1-<6 years — Black or African American0
1-<6 years — White5
1-<6 years — More than one race0
1-<6 years — Unknown or Not Reported0
6-<12 years — American Indian or Alaska Native0
6-<12 years — Asian0
6-<12 years — Native Hawaiian or Other Pacific Islander0
6-<12 years — Black or African American0
6-<12 years — White5
6-<12 years — More than one race0
6-<12 years — Unknown or Not Reported0
Total — American Indian or Alaska Native0
Total — Asian0
Total — Native Hawaiian or Other Pacific Islander0
Total — Black or African American0
Total — White10
Total — More than one race0
Total — Unknown or Not Reported0
Weight
Weight(kg)Wilate
1-<6 years16.9 ± 3.6
6-<12 years37.4 ± 5.4
Total27.2 ± 11.6
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Wilate
1-<6 years15.3 ± 1.3
6-<12 years17.7 ± 2.2
Total16.5 ± 2.1
Blood groups
Blood groups(Participants)Wilate
1-<6 years — O2
1-<6 years — A1
1-<6 years — AB0
1-<6 years — B2
6-<12 years — O2
6-<12 years — A3
6-<12 years — AB0
6-<12 years — B0
Total — O4
Total — A4
Total — AB0
Total — B2
Previous Factor (F)VIII treatment
Previous Factor (F)VIII treatment(Participants)Wilate
1-<6 years — On-demand0
1-<6 years — Prophylaxis3
1-<6 years — Combination2
6-<12 years — On-demand2
6-<12 years — Prophylaxis0
6-<12 years — Combination3
Total — On-demand2
Total — Prophylaxis3
Total — Combination5
Previous annualised bleeding rate (ABR)
Previous annualised bleeding rate (ABR)(Bleeding events per year (ABR))Wilate
1-<6 years4.8 ± 3.0
6-<12 years13.6 ± 8.9
Total9.2 ± 7.8
08

Study locations

3 sites
  • Kirov SSC Hematology and Transfusiology
    Kirov, Russian Federation
  • "National Children's Specialized Clinic "OKHMATDYT"
    Kyiv, Ukraine
  • "Western Ukrainian Specialized Children's Medical Center"
    Lviv, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Nov 2018, 11 months.

Results were first posted in Dec 2019, 1 year 1 month after primary completion.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 11 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2017
First posted
Dec 18, 2017
StartActual
Nov 22, 2017
Primary completionActual
Nov 3, 2018
CompletionActual
Nov 3, 2018
Results first posted
Dec 24, 2019
Last update
Jan 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03376516
Lead sponsor
Octapharma
Responsible party
Sponsor
First posted
Dec 18, 2017
Start date
Nov 22, 2017
Primary completion
Nov 3, 2018
Completion
Nov 3, 2018
Results posted
Dec 24, 2019
Last update
Jan 19, 2021

Study contacts

Cristina Solomon, MD
study director · Octapharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion